Drawing for MEDPRO SYSTEMS

USPTO serial 98048406

MEDPRO SYSTEMS

Reviewed by CopyMark Law Group

Reg. 7432933Status 700Registered
Filing date
Status date
Registration date
Jul 2, 2024
Examiner
BLOHM, LINDA
Law office
FILE REPOSITORY (FRANCONIA)

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with MEDPRO SYSTEMS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
035Business consulting services for life sciences, pharmaceuticals, biotechnology and medical device companies in the nature of regulatory compliance program development and enhancement and transparency program support, namely, reviewing program status and performing gap analyses, drafting programs plans, program implementation support, development and improvement of policies, standard operating procedures and codes of conduct; business consulting services in the nature of monitoring of pharmaceutical and medical device manufacturer interactions with healthcare professionals, healthcare organizations, patients, and other customers; business consulting services in the nature of auditing of pharmaceutical and medical device manufacturer interactions with and payments to healthcare professionals, healthcare organizations, patients, and other customers; business consulting services in the nature of business investigation support for internally and externally raised complaints made against a pharmaceutical or medical device manufacturer related to potential violations of their company policy or code, industry code, or law or regulation; transparency reporting regulatory submission management, namely, assisting others in preparing and filing regulatory submissions in the field of transparency reporting for pharmaceutical, biotechnology and medical device companies; business consulting services, namely, tracking and monitoring regulatory requirements for others in the field of life sciences, pharmaceuticals, biotechnology, and medical devices for regulatory compliance; business consulting services, namely, compliance program gap analysis for life sciences, pharmaceutical, biotechnology, and medical device companiesACTIVEApr 1, 2021
041Consulting services in the nature of conducting trainings for life sciences, pharmaceuticals, biotechnology, and medical device companies personnel and partners on pharmaceutical and medical device compliance program requirements, fraud and corruption laws and regulations, industry codes and best practices; consulting services, namely, developing and providing trainings for life sciences, pharmaceutical, biotechnology, and medical device companies in the field of corporate compliance and transparency programsACTIVEApr 1, 2021
042Software as a service (SaaS) services featuring software for use to assist in tracking and reporting healthcare practitioner and healthcare organization interactions and complying with international, federal, state and local spend and transparency laws and regulations; software as a service (SaaS) services featuring software to assist pharmaceutical, biotechnology and medical device companies in managing, validating and enriching healthcare organization and healthcare practitioner data attributes in connection with regulatory compliance, sales and marketing effortsACTIVEFeb 11, 2003
045Regulatory compliance consulting in the field of life sciences, pharmaceuticals, biotechnology, and medical devices; consulting services to assist life sciences, pharmaceutical, biotechnology and medical device companies in the fields of regulatory compliance, namely, compliance in the areas of aggregate spend disclosure reporting, the Prescription Drug Marketing Act, the Drug Supply Chain Security Act, Condition of Participation for Outpatient Services, Stark Law and Ohio Terminal Distributor of Dangerous Drugs requirements; regulatory compliance audits for life sciences, pharmaceutical, biotechnology and medical device companies to assist with regulatory compliance; consulting services in the field of life sciences, pharmaceutical, biotechnology and medical device corporate compliance program and transparency program development, implementation and support; providing online searchable databases and information concerning historical, current and pending laws, regulations, and guidance documents governing the life sciences industry; regulatory compliance consulting services in the field of aggregate spend disclosure reporting; regulatory and compliance information for pharmaceutical, biotechnology and medical device companies, and for entities involved in the drug and device supply chain, regarding transparency and aggregate spend, marketing, and additional compliance requirements; regulatory compliance consulting, namely, reviewing, developing, training on and assisting with the implementation and monitoring of standards, practices, procedures and policies to support regulatory compliance for companies in the fields of life sciences, pharmaceuticals, biotechnology, and medical devicesACTIVEApr 1, 2021

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 2, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED
Jul 2, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 16, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 16, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Mar 27, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 11, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Mar 5, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED
Mar 5, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 5, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Mar 1, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 1, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 1, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 26, 2024DOCKASSIGNED TO EXAMINER
Jul 22, 2023MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED
Jul 21, 2023NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 22, 2023NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance